Abstract PS08-03: Sequencing Antibody-Drug Conjugate after Antibody-Drug Conjugate in Metastatic Breast Cancer (A3 study): Multi-Institution Experience and Biomarker Analysis
Rachel O. Abelman(Massachusetts General Hospital), Aditya Bardia(UCLA Health), Beverly Moy(Global Cancer Institute), Laura M. Spring(Massachusetts General Hospital), Seth A. Wander(Harvard University), Jennifer J. Shin(Massachusetts Department of Public Health), Neelima Vidula(Harvard University), Phoebe Ryan(Harvard University), Leif W. Ellisen(Harvard University), Geoffrey Fell(Harvard University), Whitney L. Hensing(Cancer Institute (WIA)), Elizabeth Abraham(Temple College), Steven J. Isakoff(Harvard University), Andrew A. Davis(Washington University in St. Louis), Arielle J. Medford(Harvard University)
Cited by 21
Related Papers
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells
|Science Translational Medicine|2013|1.1k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k